) reported second-quarter 2013 operating earnings per share of
$1.62. The results comfortably surpassed the Zacks Consensus
Estimate of $1.52 but were a penny higher than year-ago quarter
figure. Operating earnings edged up 0.5% year over year to $759
million. A weak yen/dollar exchange rate had a negative impact of
22 cents per share on operating earnings.
Operating earnings in the reported quarter excluded the
after-tax negative impact of realized investment gains from
securities transactions and impairments of $55 million or 12
cents per share compared to a loss of $228 million or 49 cents
per share in the year-ago quarter. It also excluded other
operating losses and hedge costs on investment totalling $4
million or 1 cent a share in the reported quarter. Additionally,
a positive impact of derivative and hedging activities worth $79
million or 17 cents per share affected the operating earnings as
opposed to a negative impact of $44 million or 9 cents per share
recorded in the year-ago period.
Including one-time items, Aflac's GAAP net income in the
reported quarter surged about 84% to $889 million or $1.90 per
share against $483 million or $1.03 per share in the year-ago
period. Total acquisition and operating expenses decreased 8.7%
year over year to $1.28 billion, whereas benefits and claims
declined 9.4% to $3.41 billion.
However, total revenue for the reported quarter climbed 2.4%
year over year to $6.04 billion, also exceeding the Zacks
Consensus Estimate of $5.86 billion. A weak yen and the low-rate
environment adversely affected the top line. While Aflac Japan
contributed about 75% to the total revenue, Aflac U.S.
contributed the remaining 25%.
Total revenue in
decreased 10.7% year over year to $4.4 billion, primarily owing
to decelerated sales from the cancer, medical, bank channel and
WAYS products along with a weak average yen. Premium income from
the Japanese operations, in terms of dollars, slid 11.8% year
over year to $3.7 billion in the reported quarter.
Net investment income from the Japanese operations declined
5.4% year over year to $653 million. The growth was primarily
mitigated by a weak yen/dollar exchange rate, which was 98.76, or
18.8% weaker than the average rate of 80.19 in the year-ago
Consequently, pre-tax operating earnings stood at $940 million
in Japan, dipping 2.5% over the prior-year quarter. However,
operating margins improved to21.5% from 19.6% in the year-ago
quarter based on lower expenses.
generated revenues of $1.3 billion, up 3.5% over the prior-year
quarter. Net investment income grew 3.1% year over year to $158
million. Premiums from the U.S. operations were up 3.5% year over
year to $1.3 billion. Given the sluggishness in the U.S. market
and limited growth in new sales, total new annualized sales
inched up 1.4% year over year to $364 million as more than 90% of
the accounts come from the small business market.
Subsequently, pre-tax operating earnings in the U.S. increased
9.9% year over year to $283 million, whereas persistency
deteriorated slightly to 76.3% from 76.6% from the year-ago
As of Jun 30, 2013, total investment and cash were $103.9
billion compared with $118.2 billion at 2012-end, while
shareholder equity totaled $13.7 billion as against $16.0 billion
during the comparable period, primarily due to changes in
investment valuation. Shareholder equity per share was $29.46 at
the end of Jun 2013, up from $34.16 per share reported at the end
At the end the Jun 2013, Aflac projected its risk-based
capital ratio to be over 700%, higher than 630% at 2012-end,
while its solvency ratio in Japan is expected to be about 585%,
lower than 669% at 2012-end. During the reported quarter, net
unrealized loss on investment securities and derivatives were
$209 million as compared with a gain of $2.0 billion in the prior
Meanwhile, annualized return on average shareholder equity for
the reported quarter was 24.3% against 22.6% in the prior
quarter. On an operating basis (excluding realized investment
losses and the impact of ASC 815 on net earnings, and unrealized
investment gains/losses in shareholder equity) Aflac's return on
average shareholder equity came in at 22.1%, down from 23.4% in
the previous quarter.
Aflac bought back about 2.3 million shares that were worth
$129 million in the reported quarter. About 17.2 million shares
were available for repurchases as of Jun 30, 2013.
Concurrent with the release of the second-quarter result,
Aflac updated its 2013 outlook. Aflac Japan's third sector cancer
and medical products sales are expected to exhibit nil to 5%
growth. However, the latest alliance with Japan Post should drive
growth in the second half of 2013, particularly, in the fourth
quarter. New annualized sales in the U.S. are projected to grow
by nil to 5% in 2013, reflecting difficult comps.
Excluding currency fluctuations, Aflac anticipates reported
earnings to grow 4-7% or about $6.86-7.06 per share in 2013.
Accordingly, if the yen averages 95-105 against dollar, the
earnings growth is expected within $5.83-6.37 per share or about
5% for 2013.
Under the same currency assumptions along with a tax benefit
of 10 cents per share, operating earnings are projected to be
$1.41-1.51 per share in the third quarter of 2013. The solvency
ratio in Japan is expected within 500-600%. Further, Aflac
intends to repurchase shares worth $600 million in 2013, while
another $600-900 million of buybacks is projected for 2014.
Concurrently, the board of Aflac announced a regular cash
dividend of 35 cents per share, which is payable on Sep 3, 2013
to its shareholders of record as on Aug 21, 2013.
Earlier, on Jun 3, 2013, Aflac paid a dividend of 35 cents per
share to its shareholders of record as on May 22, 2013.
Aflac carries a Zacks Rank #3 (Hold). Other strong performers
in the insurance sector include
Everest Re Ltd.
), all of which carry a Zacks Rank #2 (Buy).
ACE LIMITED (ACE): Free Stock Analysis Report
AFLAC INC (AFL): Free Stock Analysis Report
AMERISAFE INC (AMSF): Free Stock Analysis
EVEREST RE LTD (RE): Free Stock Analysis
To read this article on Zacks.com click here.